Marc Iskowitz

Most recent articles by Marc Iskowitz

Use of Pfizer, Merck antivirals rises in step with COVID case counts
Use of Pfizer, Merck antivirals rises in step with COVID case counts
Marc Iskowitz
May 19, 2022
9:31 am

Concurrent with the most recent wave of infections, providers are dispensing more of the antiviral pills, data show.

Henry Schein names its first chief commercial officer
Henry Schein names its first chief commercial officer
Marc Iskowitz
May 18, 2022
10:02 am

Dirk Benson joins after a nearly three-decade stint with privately-held healthcare products distributor Medline Industries.

PhysIQ hires a pair of commercial execs
PhysIQ hires a pair of commercial execs
Marc Iskowitz
May 16, 2022
9:00 am

The execs will oversee the wearables firm’s life sciences practice and take the lead on marketing efforts.

Indegene nabs a pharma vet to run its commercialization team
Indegene nabs a pharma vet to run its commercialization team
Marc Iskowitz
May 12, 2022
11:16 am

Nancy Phelan will run the consultancy’s global omnichannel commercialization business.

Stratpharma appoints NA chief commercial officer
Stratpharma appoints NA chief commercial officer
Marc Iskowitz
May 11, 2022
2:46 pm

Michael Flowers joins with more than 20 years of commercial leadership experience for North America.

Carmell Therapeutics names chief business officer
Carmell Therapeutics names chief business officer
Marc Iskowitz
May 11, 2022
2:05 pm

Sebastian “Sebby” Borriello joins from SK Life Science, where he served as chief commercial officer.

GoodRx makes a trio of C-suite hires
GoodRx makes a trio of C-suite hires
Marc Iskowitz
May 11, 2022
9:15 am

The digital healthcare company named its first COO, as well as chief product and people officers.

Cerebral, updating its ADHD ads, is hit with a DOJ subpoena
Cerebral, updating its ADHD ads, is hit with a DOJ subpoena
Marc Iskowitz
May 10, 2022
10:08 am

The company, which has revised language in its ADHD ads in the face of scrutiny, said it was subpoenaed last week.

FDA refutes Bourla’s advice on 2nd course of Paxlovid
FDA refutes Bourla’s advice on 2nd course of Paxlovid
Marc Iskowitz
May 6, 2022
4:11 pm

The CEO’s suggestion for dealing with patients whose COVID symptoms relapse — taking a second course of the antiviral pill — is not supported by data, the agency said.

3 takeaways as Biogen’s Aduhelm pullback brings marketing drama to a close
3 takeaways as Biogen’s Aduhelm pullback brings marketing drama to a close
Marc Iskowitz
May 5, 2022
9:36 am

As the company largely pulls the plug on its commercial infrastructure for the prized Alzheimer’s asset, here’s what marketers can learn from the drug’s failure.

  • From Our Partners